Clinical Trial Details
| Trial ID: | L3382 |
| Source ID: | NCT01935466 |
| Associated Drug: | Pioglitazone |
| Title: | Risk of Bladder Cancer in Type 2 Diabetes Patients With Pioglitazone Therapy "PROBE" |
| Acronym: | PROBE-PIO |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Bladder Cancer |
| Interventions: | DRUG: Pioglitazone |
| Outcome Measures: | Primary: Bladder cancer rate, Kaplan-Meir survival curves will be generated for the two groups of pioglitazone users and non-pioglitazone users. All the data at the time point of interview will be considered censored. Bladder cancer rates among pioglitazone users and non-users will be compared by hazard ratio (HR) after Cox regression. Adjustment for various confounders like age, diabetes duration, region of residence, occupation, smoking, urinary tract disease, use of other medications like sulfonylurea, metformin, insulin, DPP-IV inhibitors and other cancers before baseline would be done., Prevalent bladder cancer on pioglitazone or anti diabetic drugs for 1 year | |
| Sponsor/Collaborators: | Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh |
| Gender: | MALE |
| Age: | ADULT, OLDER_ADULT |
| Phases: | |
| Enrollment: | 6107 |
| Study Type: | OBSERVATIONAL |
| Study Designs: | Observational Model: |Time Perspective: p |
| Start Date: | 2013-07 |
| Completion Date: | 2021-10 |
| Results First Posted: | |
| Last Update Posted: | 2022-01-25 |
| Locations: | Deptt of Endocrinology, Chandigarh, 160012, India |
| URL: | https://clinicaltrials.gov/show/NCT01935466 |
